Core Viewpoint - Amgen's stock presents an attractive long-term investment opportunity despite recent share price declines and upcoming patent cliffs [1][2]. Group 1: Promising Drug Developments - Amgen is developing MariTide, a weight management drug that has shown a mean weight loss of up to 20% over 52 weeks, with a favorable monthly dosing schedule [4][5]. - The anti-obesity market is rapidly growing, and MariTide could generate sales of up to $3.7 billion by 2030, helping Amgen offset losses from patent expirations [6]. - Amgen has a robust pipeline with several ongoing programs, including bemarituzumab, which has shown promising results in a phase 3 study for metastatic gastric cancer [7][8]. Group 2: Recent Product Launches - Amgen's recent product approvals, such as Imdelltra for lung cancer, Tezspire for asthma, and Uplizna for rare diseases, are expected to contribute to top-line growth [9][10]. Group 3: Financial Strength and Dividends - Amgen has a strong dividend track record, having increased its dividend by 201.3% over the past decade, with a current yield of 3.5% [11][12]. - The company's cash payout ratio of 46.5% provides room for further dividend increases, making it an attractive option for investors seeking income [12][13]. Group 4: Valuation - Amgen's shares are considered reasonably valued, with a forward price-to-earnings ratio of 12.6, lower than the healthcare industry average of 16.4 [14][15]. - The market may be pricing in upcoming patent losses, but long-term investors could benefit from potential revenue and earnings growth as new products are launched [15].

Amgen Inc. (NASDAQ:AMGN) is included among the 11 Cheap Quarterly Dividend Stocks to Buy Right Now. Is Amgen (AMGN) a Safe Bet for Income Investors in Cheap Quarterly Dividend Stocks? Amgen Inc. (NASDAQ:AMGN), a leading biotechnology company, offers investors a strong and diverse portfolio. It has more than two dozen brands, including several blockbuster drugs that each bring in over $1 billion in annual sales. Amgen Inc. (NASDAQ:AMGN)’s medicines span multiple therapeutic areas. These include Repatha, ...

REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for AVT03, Alvotech’s proposed biosimilar to Prolia® (denosumab 60 mg/mL single use pre-filed syringe) and Xgeva® (denosumab 70 mg/mL single use ...

Core Viewpoint - Alvotech has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval for its biosimilar AVT03, which is a proposed alternative to Prolia® and Xgeva® [1][4] Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to provide affordable biologic treatments to patients worldwide [7] - The company has already approved and marketed two biosimilars, with a pipeline that includes nine additional candidates targeting various diseases [7] Product Details - AVT03 is a human monoclonal antibody biosimilar candidate to Prolia® (denosumab 60 mg/mL) and Xgeva® (denosumab 70 mg/mL) [5] - Prolia® is indicated for treating osteoporosis and bone loss in specific patient populations, while Xgeva® is used to prevent bone complications in advanced cancer patients [3] Commercial Partnerships - Upon approval, AVT03 will be marketed by Alvotech's partners, STADA and Dr. Reddy's, each holding semi-exclusive commercial rights in Europe, including Switzerland and the UK [1][4] - STADA will market the biosimilar under the names Kefdensis® and Zvogra®, while Dr. Reddy's will use the names Acvybra® and Xbonzy® [4] Regulatory Status - AVT03 is currently under review by the EMA, with a final decision pending from the European Commission [4]

Core Viewpoint - The healthcare sector, particularly dividend-paying stocks like Amgen and Merck, presents solid investment opportunities due to their non-cyclical nature and consistent revenue generation even in challenging economic conditions [1][2]. Group 1: Amgen - Amgen is a leading biotech company with a diverse portfolio of over two dozen products, many of which are blockbuster drugs generating over $1 billion in annual sales [4]. - The company reported a 9% year-over-year revenue growth in Q2, reaching $9.2 billion, with non-GAAP earnings per share at $6.02, a 21% increase from the previous year [6]. - Amgen faces patent cliffs and biosimilar competition but has strong growth drivers, including Tezspire for asthma, which saw a 46% year-over-year sales increase to $342 million [7][8]. - The company has a robust dividend profile with a forward yield of 3.4%, having increased its payouts annually since 2011 [9]. Group 2: Merck - Merck is experiencing increased competition for its cancer drug Keytruda, with patent exclusivity expiring in 2028, and has faced declining sales in its vaccine franchise due to paused shipments in China [10][11]. - In Q2, Merck's revenue declined by 2% year-over-year to $15.8 billion [11]. - The company is developing a subcutaneous version of Keytruda to extend its patent life and has received approval for new products like Winrevair for pulmonary arterial hypertension [12][13]. - Merck's forward yield is currently at 3.9%, with an 88.8% increase in dividends over the past decade, making it an attractive option for dividend investors despite current challenges [15].

Core Viewpoint - The company has received FDA approval for two products, BILDYOS and BILPREVDA, which enhances its international market presence and product recognition [1][2]. Product Approvals - BILDYOS (60 mg/mL) is approved for treating osteoporosis in high-risk postmenopausal women, increasing bone mass in high-risk men, and treating osteoporosis caused by glucocorticoids in both men and women [1]. - BILPREVDA (120 mg/1.7 mL) is approved for preventing bone-related events in multiple myeloma and solid tumor patients, treating giant cell tumors of bone, and managing refractory hypercalcemia in malignancies after bisphosphonate treatment [1]. FDA Review Process - The FDA's approval was based on comprehensive reviews of comparative studies between HLX14 (the active ingredient in BILDYOS and BILPREVDA) and its reference drug Prolia, demonstrating high similarity in quality, safety, and efficacy [2]. - The production facilities for HLX14 have passed FDA pre-license inspections, confirming compliance with cGMP requirements [2]. Market Impact - With the approval of BILDYOS and BILPREVDA, the company now has six products approved overseas and three in the U.S., indicating a deepening of global commercialization efforts [2]. - This approval signifies further recognition of the company's products in international markets, enhancing their global influence [2].

Core Insights - Amgen's stock has increased by 13.5% year-to-date, outperforming the industry, sector, and S&P 500 Index [1][9][10] Revenue Drivers - Key medicines such as Repatha, Evenity, and Blincyto, along with newer products like Tavneos and Tezspire, are driving sales growth, compensating for declines in oncology biosimilars and mature products like Enbrel [4][7][10] - Revenues increased by 9.4% in the first half of 2025 due to rising patient demand for innovative medicines [6] - Rare disease drugs from the acquisition of Horizon Therapeutics are also contributing to revenue growth [7] Pipeline Developments - Amgen is focusing on the obesity candidate MariTide, which is in phase III studies, and has shown promising results in clinical trials [12][14] - Additional indications for existing drugs like Kyprolis and Uplizna are being evaluated, with potential approvals expected to drive further growth [8][10] Biosimilars Performance - New biosimilars launched in 2025, including Wezlana and Pavblu, generated significant sales, contributing to a total of $1.4 billion from biosimilars in the first half of 2025 [18][20] - Amgen's biosimilars have accumulated nearly $12 billion in sales since their first launch in 2018, enhancing top-line growth [20] Competitive Landscape - Sales of key drugs Prolia and Xgeva are expected to decline due to biosimilar competition following patent expirations [22] - Pricing pressures and competitive challenges are impacting sales of some products, particularly Otezla and Lumakras [23] Valuation and Estimates - Amgen's shares are trading at a price/earnings ratio of 13.53, lower than the industry average of 14.85, indicating reasonable valuation [24] - Consensus estimates for earnings per share have increased for 2025 and 2026, reflecting positive sentiment [27][29]

Group 1: Overview of High-Yielding Stocks - The Dow Jones Industrial Average is a prime source for reliable dividend-paying stocks, which have shown the ability to generate profits in various economic conditions [2] - The average dividend yield in the Dow is currently 1.6%, with UnitedHealth Group, Coca-Cola, and Amgen offering above-average yields [3] Group 2: UnitedHealth Group - UnitedHealth Group's stock price fell significantly after the company suspended its 2025 outlook and announced a CEO exit, yet it raised its dividend payout by 76.8% over the past five years, currently offering a 2.7% yield [5][6] - The company mispriced premiums for 2025 due to higher-than-expected healthcare costs and increased care usage by new members [6] - Despite recent challenges, the management team is expected to avoid similar mispricing errors in the future [7] Group 3: Coca-Cola - Coca-Cola's stock is near its all-time high, with a dividend increase of 24.4% over the past five years, currently yielding 2.9% [8][9] - The company has a strong competitive advantage with its popular beverage brands, allowing for consistent profits, and it announced a dividend raise for the 63rd consecutive year [9] - Although sugary soda sales are declining, Coca-Cola's BodyArmor brand is gaining market share, contributing to revenue growth [10] Group 4: Amgen - Amgen's shares are trading about 12% below their all-time high, with a dividend increase of 48.8% over the past five years, currently offering a 3.2% yield [11] - The company faces competition for its top revenue products, Enbrel and Prolia, but has launched new products that are driving double-digit sales increases [12] - Amgen's sales growth is expected to remain strong in the coming decade, despite the challenges posed by biosimilars [12]

Core Insights - Amgen (AMGN) reported strong quarterly performance with second-quarter 2025 earnings and sales exceeding estimates, showcasing consistent top-line growth [1][3] - Total revenues increased by 9% year over year to $9.2 billion, with product revenues also rising by 9% to $8.77 billion, driven primarily by volume growth despite declining drug prices [1][6] Revenue Performance - Amgen's total revenues rose 9% year over year to $9.2 billion, with product revenues increasing to $8.77 billion [1][6] - Fifteen of Amgen's products, including Repatha, Blincyto, Tezspire, Uplizna, Tavneos, and Evenity, achieved double-digit volume growth [2] - Rare disease drugs contributed significantly, with sales rising 19% year over year to nearly $1.4 billion, now annualizing at over $5 billion [8] Key Drug Performance - Repatha generated revenues of $696 million, up 31% year over year, driven by a 36% increase in volume [5] - Evenity recorded sales of $518 million, up 32% year over year, benefiting from solid volume growth [6] - Prolia revenues decreased by 4% year over year to $1.12 billion due to lower pricing [7] - Blincyto sales rose 45% year over year to $384 million, driven by broad prescribing [12] Oncology and Biosimilars - Amgen's oncology portfolio grew 14% year over year, generating over $2.2 billion in sales [12] - Biosimilar sales surged 40% year over year to $661 million, with new launches contributing to growth [15][16] Established Products and Inflammation Drugs - Sales of established products decreased by 5% year over year to $533 million [22] - Otezla sales increased by 14% to $618 million, driven by volume growth [19] Future Outlook - Amgen raised its revenue and earnings outlook for 2025, expecting total revenues in the range of $35 billion to $36 billion [23] - Key drugs like Repatha, Evenity, Tezspire, and oncology drugs are expected to drive growth, although pricing pressures may offset some gains [24][25]

Core Viewpoint - Amgen Inc. reported strong second-quarter results, surpassing analyst expectations, but its shares are trading lower due to ongoing investor concerns about its experimental weight-loss drug, MariTide [1][4]. Financial Performance - Adjusted earnings for the second quarter were $6.02 per share, a 21% increase year over year, exceeding the consensus estimate of $5.24 [1]. - Quarterly sales reached $9.18 billion, up 9%, also beating Wall Street's estimate of $8.87 billion [1]. - Product sales grew by 9%, driven by a 13% increase in volume, partially offset by a 3% decrease in net selling price [2]. Future Outlook - Amgen raised its fiscal year 2025 adjusted earnings guidance from a range of $20.00-$21.20 per share to $20.20-$21.30, compared to the consensus of $20.89 [3]. - The sales outlook was increased from $34.30 billion-$35.70 billion to $35 billion-$36 billion, against a consensus of $35.29 billion [3]. Product Focus - Investor attention is heavily focused on MariTide, an experimental weight-loss drug, with ongoing Phase 2 studies for chronic weight management and type 2 diabetes [4][5]. - Data readout for the studies is expected in the fourth quarter of 2025 [4][5]. - Analysts express concerns about the trial's ability to address tolerability issues that investors are debating [5]. Competitive Landscape - Amgen has seen clinical and commercial success with several products, including Repatha and Evenity, which support long-term growth prospects [6]. - The company faces near-term challenges from legacy products and competition from biosimilars, but upcoming clinical catalysts are expected to generate investor interest [6]. Stock Performance - As of the latest check, Amgen's stock is trading lower by 5.10% at $284.97 [7].